Building on its flagship anticancer agent, TS-1, for which it has established evidence for various kinds of cancers, especially gastric cancer, Taiho Pharmaceutical has been conducting research and development of drugs in new categories based on its accumulated findings and knowhow. One strong result was the discovery of LONSURF, which has a novel mechanism of action. Taiho seeks to contribute to the diversification of cancer treatment around the world. It works on anticancer agents with various mechanisms such as inhibition of protein functions involved in cancer proliferation, survival, angiogenesis or drug resistance, as well as anticancer agents that target cancer cell-specific metabolism and also cancer immunity, an area that has developed remarkably in recent years.
Leveraging the experience and technology cultivated during the development of the Th2 cytokine production inhibitor, IPD, Taiho Pharmaceutical continually pursues drugs with novel mechanisms of action that are applicable to rare diseases as well as refractory diseases such as autoimmune diseases that have high medical needs.
Leveraging the wealth of findings and experience gained from BUP-4, which improves symptoms of urinary incontinence and frequent urination, Taiho Pharmaceutical has elucidated the pathology behind many kinds of urinary incontinence and disorders of micturition. Taking advantage of this experience, Taiho is exploring new types of drugs for unmet medical needs.